About Immunome, Inc.
https://immunome.comImmunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system.
CEO
Clay B. Siegall
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 119
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Guggenheim
Buy
Lake Street
Buy
Evercore ISI Group
Outperform
Wedbush
Outperform
Stephens & Co.
Overweight
JP Morgan
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FMR LLC
Shares:13.06M
Value:$271.06M
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:8.42M
Value:$174.76M
BLACKROCK, INC.
Shares:5.82M
Value:$120.88M
Summary
Showing Top 3 of 165
About Immunome, Inc.
https://immunome.comImmunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 ▼ | $10.95M ▼ | $-57.46M ▼ | 0% ▲ | $-0.65 ▼ | $-56.87M ▼ |
| Q2-2025 | $4.01M ▲ | $49.77M ▲ | $-43.4M ▼ | -1.08K% ▲ | $-0.5 ▲ | $-45.76M ▼ |
| Q1-2025 | $2.93M ▲ | $47.56M ▼ | $-41.64M ▲ | -1.42K% ▲ | $-0.52 ▲ | $-43.91M ▲ |
| Q4-2024 | $2.74M ▼ | $85.71M ▲ | $-80.25M ▼ | -2.93K% ▼ | $-1.28 ▼ | $-55M ▼ |
| Q3-2024 | $2.91M | $53.43M | $-47.1M | -1.62K% | $-0.78 | $-43.24M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $272.64M ▲ | $299.38M ▲ | $35.46M ▲ | $263.92M ▼ |
| Q2-2025 | $268.04M ▼ | $296.29M ▼ | $27.02M ▼ | $269.27M ▼ |
| Q1-2025 | $317.32M ▲ | $342.69M ▲ | $35.57M ▼ | $307.13M ▲ |
| Q4-2024 | $217.3M ▼ | $240.24M ▼ | $59.08M ▲ | $181.16M ▼ |
| Q3-2024 | $240.13M | $256.9M | $41.99M | $214.91M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-57.46M ▼ | $-40.51M ▲ | $123.88M ▲ | $45.39M ▲ | $128.76M ▲ | $-41.63M ▲ |
| Q2-2025 | $-43.4M ▼ | $-49.4M ▲ | $-64.17M ▼ | $-55K ▼ | $-113.63M ▼ | $-50.31M ▲ |
| Q1-2025 | $-41.64M ▲ | $-53.05M ▼ | $5.09M ▼ | $162.23M ▲ | $114.26M ▲ | $-56.72M ▼ |
| Q4-2024 | $-80.25M ▼ | $-42.06M ▼ | $9.76M ▼ | $20.09M ▲ | $-12.22M ▼ | $-43.44M ▼ |
| Q3-2024 | $-47.1M | $-34.17M | $24.1M | $305K | $-9.76M | $-35.71M |
CEO
Clay B. Siegall
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 119
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Guggenheim
Buy
Lake Street
Buy
Evercore ISI Group
Outperform
Wedbush
Outperform
Stephens & Co.
Overweight
JP Morgan
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FMR LLC
Shares:13.06M
Value:$271.06M
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:8.42M
Value:$174.76M
BLACKROCK, INC.
Shares:5.82M
Value:$120.88M
Summary
Showing Top 3 of 165